Drug Index

Drotrecogin Alfa

Synonym :

Recombinant Human activated Protein C

Mechanism :

Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability.

Indication :

  • For reduction of mortality in patients with severe sepsis.

Contraindications :

Active internal bleeding.

Recent (within 3 months) hemorrhagic stroke.

Recent (within 2 months) intracranial/intraspinal surgery/severe head trauma.

Trauma patients with an increased risk of life-threatening bleeding.

Presence of an epidural catheter.

Known or suspected intracranial neoplasm or mass lesion.

Known hypersensitivity to drotrecogin or any component.

Dosing :

IV infusion rate:
24 mcg/kg/hr for 96 hours. Maximum allowed infusion time is 168 hours.

Adverse Effect :

Intracranial, GI, genitourinary or skin hemorrhages.

Interaction :

Antiplatelet agents: Such as clopidogrel and other anticoagulants(Heparin, warfarin) may enhance the adverse/toxic effect of Drotrecogin Alfa.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in normal renal function
HDUnlikely to be dialysed. Dose as in normal renal function
HDF/High fluxUnlikely to be dialysed. Dose as in normal renal function
CAV/VVHDUnlikely to be dialysed. Dose as in normal renal function

Hepatic Dose :

Use is contraindicated in severe hepatic impairment.
12/12/2023 15:54:48 Drotrecogin Alfa
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0